Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RBI-4000 in Healthy Volunteers
NCT06048770Phase 1Terminated
- Sponsor
- Replicate Bioscience
- Start
- Sep 2023
- Primary completion
- Jul 2024
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of RBI-4000 in rabies (5 arms), sponsored by Replicate Bioscience. Primary endpoints: Treatment-emergent Adverse Events and Serious Adverse Events and Immunogenicity of RBI-4000 Measured by Neutralizing Antibody Titers. Started Sep 2023; status: terminated.
02
Drugs
RBI-4000
03
Conditions
rabies
Beyond the preview
Go deeper on NCT06048770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06048770.